Key Takeaways
- UBS lifted IBM from Sell to Neutral following a ~22% decline in 2026, pointing to improved risk/reward dynamics
- The tech giant currently trades at ~18.5x its 2026 EPS estimate of $12.43, representing a mid-teens discount versus broader market multiples
- Anthropic’s Claude Code announcement regarding COBOL modernization tools drove the selloff, raising concerns about IBM’s mainframe revenue stream
- Q4 results exceeded expectations with $4.52 EPS versus $4.33 consensus, while revenue reached $19.69B — reflecting 12.2% annual growth
- Wall Street maintains a Moderate Buy consensus with analysts targeting $330.07 on average
UBS has elevated its rating on International Business Machines (IBM) to Neutral from Sell, highlighting improved risk/reward dynamics following a significant decline during early 2026.
International Business Machines Corporation, IBM
Shares of IBM have declined approximately 22% during the current year while trailing the S&P 500 by close to 27% across the trailing 12-month period.
The stock began Wednesday’s session at $229.34, significantly below its 52-week peak of $324.90.
A substantial portion of the recent weakness stems from a specific trading session. On February 23, IBM tumbled approximately 13% following Anthropic’s announcement that its Claude Code tool would include COBOL modernization capabilities — sparking concerns that artificial intelligence could automate legacy systems and pressure IBM’s mainframe and consulting operations.
Multiple analysts, including teams at Wedbush and Evercore, characterized that decline as excessive. They highlighted IBM’s robust customer retention and the difficulties associated with mainframe migration as factors suggesting the competitive threat may be exaggerated.
UBS shared this perspective, noting that competitive risks to IBM’s Z mainframe platform appear adequately reflected in current valuations. The investment bank pointed to customer retention dynamics, data sovereignty mandates, and IBM’s comprehensive technology stack — featuring quantum-safe encryption capabilities — as factors making mainframe displacement unlikely in the foreseeable future.
Current Valuation Metrics
IBM currently commands roughly 18.5 times its 2026 EPS projection of $12.43 and 17.5 times its 2027 forecast of $13.13. This valuation represents a mid-teens discount relative to broader market multiples.
UBS maintained its $236 price objective, calculated using 18 times its 2027 EPS projection. Under an optimistic scenario, UBS envisions shares reaching $312 if software expansion accelerates and profit margins widen. Under a pessimistic scenario, the stock could decline to $134 if AI-powered coding solutions significantly disrupt IBM’s software and infrastructure operations.
IBM provided guidance for 2026 free cash flow of $15.7 billion, translating to approximately $16.25 per share — representing roughly a 7% free cash flow yield. UBS noted this figure aligns with comparable large-scale software enterprises experiencing mid single-digit revenue expansion.
UBS anticipates IBM will generate 3% to 4% organic revenue expansion across upcoming years. The firm identified decelerating momentum at Red Hat, ambiguity surrounding the Consulting division as artificial intelligence transforms client requirements, and continued headwinds facing IBM’s infrastructure operations as persistent challenges.
Latest Quarterly Performance and Wall Street Views
IBM’s latest quarterly performance demonstrated strength. The technology company posted Q4 EPS of $4.52, surpassing the $4.33 consensus projection. Revenue totaled $19.69 billion, exceeding forecasts of $19.23 billion while advancing 12.2% year-over-year.
IBM additionally announced a quarterly dividend of $1.68 per share, with distribution scheduled for March 10. This represents an annualized yield of approximately 2.9%.
Director David N. Farr acquired 1,000 shares at $304.00 on January 30, expanding his total position to 9,258 shares.
Vestmark Advisory Solutions expanded its IBM position by 413.7% during Q3, purchasing 6,209 shares to reach a total holding of 7,710.
Throughout Wall Street, IBM maintains a consensus Moderate Buy rating with an average price objective of $330.07, derived from one Strong Buy, eleven Buy, seven Hold, and one Sell rating.
